

Sub 1

1. A method for treating proliferative skin diseases comprising the administration of an effective amount of tazarotene and an effective amount of a corticosteroid.

5

2. The method of claim 1 wherein said corticosteroid is selected from the group consisting of fluocinolone acetonide, mometasone furoate, fluocinonide, diflorasone diacetate, fluticasone propionate, betamethasone dipropionate, clobetasol propionate, betamethasone valerate.

10

Sub C

3. The method of claim 1 wherein tazarotene is applied as a 0.1% gel.

4. The method of claim 1 wherein said corticosteroid is a mid- or high-potency corticosteroid.

15

Sub 92

5. The method of claim 4 wherein said corticosteroid is selected from the group consisting of mometasone furoate and fluocinolone acetonide.

6. A method for treating psoriasis in a human subject by topically applying to the psoriatic skin of said subject an effective amount of tazarotene and an effective amount of a corticosteroid.

20

Sub C

7. The method of claim 6 wherein tazarotene is applied as a 0.1% gel.

25

8. The method of claim 7 wherein said corticosteroid is a cream.

9. The method of claim 8 wherein said corticosteroid is a mid- or high-potency corticosteroid.

Sub

11. ~~The method of claim 6 wherein tazarotene is administered once daily in the evening and the corticosteroid is administered once daily in the morning.~~

[illegible]